Home > Aplastic and Other Anemias > Efficacy > Other Rare Anemias

EXJADE Reduces Iron Toxicity
in Other Rare Anemias

Serum ferritin trends in rare anemia patients from the EPIC Study, the largest chelation trial to date1

In 2010, the 1-year EPIC study showed that EXJADE effectively reduced serum ferritin levels in patients with rare anemias who suffered from iron toxicity (n=43). These rare anemias primarily included pure red cell aplasia and other hemolytic anemias.1

Substantial Reduction in Serum Ferritin Levels1,2
EXJADE: Substantial Reduction in Serum Ferritin Levels

EXJADE has shown efficacy in reducing iron toxicity with decreased
liver iron concentration levels across rare anemias

In 2007, a 1-year study in patients across a range of anemias (N=184) showed that EXJADE reduced liver iron concentration in patients with other rare anemia patients, which included Fanconi's and sideroblastic anemia.3

EXJADE Reduces Liver Iron Concentration
in Patients With Rare Anemias2, 3
EXJADE: Reduction in LIC in Patients with Rare Anemias

EXJADE FAQ

Find answers to all of
your EXJADE questions.

Learn more

SAFETY PROFILE
ACROSS ANEMIAS

Learn more